Townson Sharon
Chief Scientific Officer at GLUE
- Sold, on record
- $424k
- Dollars the filings state
- Form 4 sales
- 5
- Latest Jul 6, 2026
- Form 144 notices
- 1
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- GLUEMonte Rosa Therapeutics, Inc.Chief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale GLUENo planJan 5, 2026 2026
Sold 3,155 shares at $15.17 ($48k)
Townson Sharon, Chief Scientific Officer
No 10b5-1 planSold 4.4% of holdings ($1.1M position)67,845 shares leftFirst sale on recordFiling
- 2 Form 144 notice GLUENoticeMay 29, 2026 +144 days
Filed to sell 24,000 shares ($465k)
Townson Sharon, Officer
10b5-1 planFiling
- 3 Form 4 sale GLUERoutineMay 29, 2026 same day
Sold 6,000 shares at $19.87 ($119k)
Townson Sharon, Chief Scientific Officer
10b5-1 planSold 8.1% of holdings ($1.5M position)67,845 shares leftFollows a Form 144Filing
- 4 Form 4 sale GLUERoutineJun 17, 2026 +19 days
Sold 3,000 shares at $19.00 ($57k)
Townson Sharon, Chief Scientific Officer
10b5-1 planSold 4.2% of holdings ($1.3M position)67,845 shares leftFollows a Form 144Filing
- 5 Form 4 sale GLUERoutineJun 23, 2026 +6 days
Sold 3,000 shares at $20.00 ($60k)
Townson Sharon, Chief Scientific Officer
10b5-1 planSold 4.2% of holdings ($1.4M position)67,845 shares left1x usual sizeFollows a Form 144Filing
- 6 Form 4 sale GLUERoutineJul 6, 2026 +13 days
Sold 6,000 shares at $23.31 ($140k)
Townson Sharon, Chief Scientific Officer
10b5-1 planSold 8.1% of holdings ($1.7M position)67,845 shares left1.9x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (6)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | Jul 7, 2026 | GLUE | Chief Scientific Officer | Form 4 sale | 6,000 | $140k | 8.1% | Routine | SEC |
| Jun 23, 2026 | Jun 25, 2026 | GLUE | Chief Scientific Officer | Form 4 sale | 3,000 | $60k | 4.2% | Routine | SEC |
| Jun 17, 2026 | Jun 18, 2026 | GLUE | Chief Scientific Officer | Form 4 sale | 3,000 | $57k | 4.2% | Routine | SEC |
| May 29, 2026 | Jun 1, 2026 | GLUE | Chief Scientific Officer | Form 4 sale | 6,000 | $119k | 8.1% | Routine | SEC |
| May 29, 2026 | May 29, 2026 | GLUE | Officer | Form 144 notice | 24,000 | $465k | Notice | SEC | |
| Jan 5, 2026 | Jan 5, 2026 | GLUE | Chief Scientific Officer | Form 4 sale | 3,155 | $48k | 4.4% | No plan | SEC |